# A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

> **NCT07157033** · PHASE1,PHASE2 · RECRUITING · sponsor: **Xerient Pharma** · enrollment: 36 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma
- Locally Advanced Pancreas Cancer
- Locally Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** XER-001

## Key facts

- **NCT ID:** NCT07157033
- **Lead sponsor:** Xerient Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-07-31
- **Final completion:** 2034-07-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07157033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07157033, "A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07157033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*